tPLGA nanoparticles combined with CCL2/CCR2 inhibitor mitigate post-thrombolytic hemorrhagic transformation

Puntos clave

• This research aims to examine the effect of tPLGA nanoparticles and CCL2/CCR2 inhibition on preventing hemorrhagic transformation after thrombolysis.
• Utilized an MMP-9-responsive tPLGA nanoplatform for targeted delivery of tPA.
• Incorporated CCL2/CCR2 inhibitors to assess changes in neuroinflammation.
• Evaluated the preservation of blood-brain barrier (BBB) integrity post-treatment.
• CCL2/CCR2 inhibition significantly reduced neuroinflammation following treatment.
• tPLGA nanoparticles effectively facilitated targeted thrombolysis without increasing hemorrhagic transformation rates.
• Preservation of BBB integrity was observed, indicating improved safety profiles.